Recall Issued on Naturalyte and GranuFlo Dialysis Products

July 18, 2012

Ennis & Ennis, P.A. Announces Free Nationwide Consultations for Patients Affected by Fresenius’ Naturalyte and GranuFlo Recall

(PRWEB) July 18, 2012

On June 27, 2012, the FDA issued a recall for Fresenius Medical Care North America’s dialysis products, Naturalyte Liquid Acid Concentrate and Naturalyte GranuFlo (powder) Acid Concentrate, due to a risk of potentially fatal serum bicarbonate levels. Naturalyte Liquid and Naturalyte GranuFlo are dialysis products.

On November 4, 2011, Fresenius sent an internal memo to doctors in the company´s dialysis centers informing of the risk and noted that 941 hemodialysis patients using the company´s products experienced cardiac arrest in 2010. However, Fresenius failed to inform the FDA and other facilities that used the product. It wasn´t until March 2012, when the FDA received an anonymous copy of the November internal memo, that other facilities became aware of this fatal danger.

If you have a loved one who suffered a cardiovascular event while or shortly after receiving dialysis with Naturalyte Liquid or Naturalyte GranuFlo products, contact the lawyers of Ennis & Ennis, P.A. today for a free nationwide confidential consultation by calling toll free 1-800-856-6405 or by completing an online case evaluation form.

Ennis & Ennis, P.A. has been representing clients individually since 1986 and has recovered over $100 million in settlements for its clients.

Ennis & Ennis, P.A. is also investigating cases involving Accutane, Actos, Avandia, Fosamax, Pradaxa, Plavix, Paxil/Birth Defect, Zoloft/Birth Defect, Prozac/Birth Defect, Depuy Hip Recall, Zimmer Hip Recall, Wright Conserve Hip, Wright Profemur Hip, all Metal-on-Metal Hips, Medtronic Infuse Bone Graft, Tekturna, Reglan, Yaz, Yasmin and Ocella Birth Control Pills.

Remember the law limits the time in which a claim can be filed, so don’t wait to explore your legal rights.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/7/prweb9708914.htm

Source: prweb

comments powered by Disqus